Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study

Shan, Qinge; Li, Zhenxiang; Lin, Jiamao; Guo, Jun; Han, Xiao; Song, Xinyu; Wang, Zhehai

doi:10.1155/2020/4784701

Cited by 9 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, it can indicate that hospice care is an important factor in good family relationships for patients with advanced NSCLC. 19,25,26 We found it interesting that patients with single bone metastases in NSCLC have longer survival than patients with multiple bone metastases. Because multiple bone metastases in NSCLC usually indicate the high activity and malignancy of these tumor cells, the prognosis is poorer.…”

Section: Discussionmentioning

confidence: 99%

“…can give patients a “placebo”. 25 This may explain why the survival of BM in married NSCLC patients is better than that in unmarried patients. Moreover, the probability of survival at 3-, 6-, and 12-months for CSS was maintained at about 80%, which is consistent with previous studies that showed that BM of NSCLC patients with positive factors such as medical coverage and family life had higher CSS levels.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis

Dong¹,

Deng²,

Mok³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Bone metastasis (BM) is the most common site of metastasis in non-small cell lung carcinoma (NSCLC). We aimed to construct and validate 2 novel nomograms predicting the 3-, 6-, and 12-months overall survival (OS) and cancer-specific survival (CSS). Methods: The clinical data of 7480 patients between 2010 and 2016 were enrolled from the Surveillance, Epidemiology, and End Results database (SEER). The patients were allocated randomly to training and validation cohorts in a 7:3 ratio. Cox proportional hazards regression models were used to identify prognostic risk factors and establish 2 nomograms. The prediction accuracy of nomograms was assessed by C-index, the area under the ROC curve (AUC), and calibration curves. Results: A total of 244998 NSCLC patients were identified between 2010 and 2016, with 7480 found with BM, accounting for 3.1%. Overall, 7480 patients were enrolled in the OS nomogram construction and were randomized to the training set (n = 5236) and the validation set (n = 2244). Age, sex, race, marital status, histology, grade, primary site, T stage, N stage, liver metastasis, surgery, radiotherapy, and chemotherapy were found to correlate with OS. A total of 7422 samples were included in the CSS nomogram construction, randomly grouped into training set (n = 5195) and the validation set (n = 2227). Age, sex, race, histology, grade, primary site, T stage, N stage, brain metastasis, liver metastasis, surgery, radiotherapy, and chemotherapy were associated with CSS. Two nomograms were conducted to predict the 3-, 6-, and 12-months OS and CSS. The ROC curves and exhibited good performance for predicting OS and CSS. Conclusion:We established and validated 2 high-performance nomograms to assist clinical doctors in making personalized treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis

Dong¹,

Deng²,

Mok³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Our results supported evidence from previous studies indicating that lung metastasis predicted the best chance of survival while liver metastasis predicted worst outcomes in patients with advanced NSCLC. 22,23 Previous studies have shown that 19del predicted a better PFS and OS than L858R in patients treated with first-line EGFR-TKIs. 24,25 In the present work, we also found that harboring 19del was associated with favorable PFS in patients treated with icotinib as first-line therapy.…”

mentioning

confidence: 99%

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer

Wang

Shi

Feng

et al. 2021

CMAR

View full text Add to dashboard Cite

Several studies have revealed the prognostic value distant metastasis in non-smallcell lung cancer (NSCLC) patients receiving first-line epidermal growth factor receptor (EGFR) inhibitors. However, the question of whether the specific metastatic site could predict survival outcomes remain elusive. This study evaluated the prognostic value of specific metastatic site at diagnosis in first-line icotinib-treated patients with EGFRmutated advanced NSCLC. Methods: A total of 216 patients with EGFR-mutated stage IV NSCLC who received firstline icotinib treatment were retrospectively enrolled. The associations between the presence of distant metastasis to certain organs at diagnosis and survival outcomes were analyzed. Patients and methods: The presence of distant metastases was not associated with progression-free survival. Patients with liver metastasis showed a significantly shorter OS than those without liver metastasis (14.6m vs 33.0m, p=0.024). Patients with brain metastasis showed a marginally shorter OS than those without brain metastasis (26.5m vs 33.8m, p=0.051). Patients with lung metastasis showed a significantly longer OS than those without lung metastasis (36.0m vs 28.6m, p=0.038). Multivariable Cox regression analysis showed the presence of liver metastasis (HR [hazard ratio]: 2.265, 95% CI [confidence interval]: 1.239-4.139, p=0.008) and brain metastasis (HR: 1.493, 95% CI: 1.012-2.202, p=0.043) were independent predictors for unfavorable OS, while lung metastasis (HR: 0.669, 95% CI: 0.460-0.971, p=0.034) was an independent predictor for favorable OS. Conclusion: The presence of liver and brain metastasis predicted unfavorable OS, while the presence of lung metastasis predicted favorable OS in first-line icotinib-treated patients with EGFR-mutated stage IV NSCLC.

show abstract

“…Shan et al indicated that the location of the tumor may affect the prognosis of patients with stage IV NSCLC, and primary tumors originating in different lobes had various trends in metastasizing to different organs. Upper lobe tumors more easily metastasized to the brain, middle lobe tumors were more likely to lead to lung metastasis, and lower lobe tumors tended to result in bone metastasis and lung metastasis (15). Ketchedjian and colleagues reported that tumors in the superior segment had a higher potential to induce mediastinal metastasis compared with those from the basal segment (45% vs. 17%, P=0.0003), and there was a significant difference in prognosis between superior segment and basal segment tumors only when tumors were of N2 status (16).…”

Section: Discussionmentioning

confidence: 99%

Survival rates of patients with tumors originating in different segments of the left upper lung in stage I to III non-small cell lung cancer

Xiao

Luo

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: The aim of this research was to evaluate the effect of spatial location of tumors on the prognosis of patients with left upper lung non-small cell lung cancer (NSCLC), with a focus on the S1+2+3 and lingual segment.Methods: A total of 486 patients who underwent lobectomy and systematic lymph node dissection were collected retrospectively in this study (354 S1+2+3 and 132 lingual segment patients). Factors impacting survival were assessed via univariate analyses, multivariate analyses, and log-rank tests.Results: Compared with tumor location in S1+2+3, lingual segment tumor location of stage II to III left upper lung NSCLC patients was significantly associated with a better 5-year disease-free survival (DFS) (P=0.041). Multivariate analysis results showed that tumor location in the lingual segment was a good independent prognostic factor of stage II to III left upper lung NSCLC patients [hazard ratio (HR) =0.602, 95% confidence interval (CI): 0.149-0.865, P=0.006). However, in stage I left upper lung NSCLC, tumor location (HR =1.069, 95% CI: 0.571-2.000, P=0.835) was not an independent prognostic factor, and only T2 (HR =2.422, 95% CI: 1.271-4.620, P=0.007) was an independent worse prognosis factor.Conclusions: Tumor location in the lingual segment of left upper lung stage II to stage III NSCLC is a good independent prognostic factor compared with S1+2+3. Nevertheless, tumor location does not impact the prognosis of patients with stage I NSCLC in the left upper lung.

show abstract

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study

Cited by 9 publications

References 39 publications

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer

Survival rates of patients with tumors originating in different segments of the left upper lung in stage I to III non-small cell lung cancer

Contact Info

Product

Resources

About